Weekly systemic cisplatin plus locoregional hyperthermia: an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area

Int J Hyperthermia. 2007 Aug;23(5):443-50. doi: 10.1080/02656730701549359.

Abstract

Purpose: Patients with recurrent cervical carcinoma within a previously irradiated area respond poorly to chemotherapy. We have treated these patients with simultaneous cisplatin and hyperthermia (CDDP + HT) and investigated response, toxicity, palliative effect and survival.

Materials and methods: Between 1992 and 2005 47 patients received CDDP + HT. Response was evaluated by gynaecologic examination and CT-scan. The Common Toxicity Criteria (CTC) were used for evaluation of toxicity and palliative effect. The Kaplan-Meier method was used to estimate survival, and Cox regression analysis to evaluate the influence of prognostic factors.

Results: The objective response rate was 55%, palliation was achieved in 74% and operability in 19% of patients. Two patients are currently disease free at 9 years and 18 + months following treatment and 2 remained disease free until death by other causes. The median survival was 8 months and was influenced by duration of disease free interval and tumour diameter. Grade 3-4 haematological toxicity was observed in 36% of patients and renal toxicity was maximum grade 2.

Conclusion: CDDP + HT results in a high response rate and acceptable toxicity in patients with recurrent cervical cancer.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Cisplatin / administration & dosage*
  • Combined Modality Therapy
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperthermia, Induced / methods*
  • Kaplan-Meier Estimate
  • Longitudinal Studies
  • Middle Aged
  • Neoplasm Recurrence, Local / prevention & control
  • Palliative Care
  • Regression Analysis
  • Salvage Therapy
  • Survival Rate
  • Treatment Outcome
  • Uterine Cervical Neoplasms / therapy*

Substances

  • Antineoplastic Agents
  • Cisplatin